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Abstract: Several genetic investigations have been attempted to elucidate the association of gene polymorphism of 
angiotensin-converting enzyme (ACE) in coronary artery disease. This study was conducted to investigate the role 
of gene polymorphism of ACE in patients with coronary artery disease. The study included fifty-six numbers of 
patients with atherosclerotic coronary artery disease where proven angiographically and fifty-six numbers of healthy 
individuals of sex matched as a control group. The patients and control group were subjected to routine 
investigations, assays like, serum cholesterol, triglycerides, high-density Lipoprotein-cholesterol (HDL-C), low-
density lipoprotein-cholesterol (LDL-C). Genomic DNA was extracted and analyzed for angiotensin-converting 
enzyme insertion/deletion polymorphism using polymerase chain reaction (PCR). When we compared the genotypes 
of patients with coronary artery disease and controls, it was observed that all three genotypes were not statistically 
different also no significant difference of alleles in ACE gene genotypes was found. Inpatient serum cholesterol, 
triglyceride and HDL-C (P <0.001, P <0.001 and P <0.001: respectively) showed a significant increase than the 
control group. In patients, LDL-C level was not more significant than controls. In the evaluated population, we 
conclude that the gene I/D polymorphism for ACE are not risk associated and may not be a useful marker for 
coronary artery disease. 
 
Keywords: Angiotensin-Converting enzyme; Genotypes; Polymorphism; Coronary artery disease. 
 
 
1. Introduction 
 
Coronary artery disease (CAD) is the underlying 
cause for most of the ischemic cardiac events and can 
result in myocardial infarction, congestive heart failure, 
cardiac arrhythmias, and sudden cardiac death. 
Clinically significant CAD in men under 40 and 
premenopausal women is uncommon, but the risk is 
more with increased age as well as in the presence of 
risk factors such as smoking, hypertension, diabetes, 
high cholesterol, and family history of heart disease [1]. 
The prevalence of CAD varies epidemiologically and 
among different populations. Familial studies have 
shown that genetic and environmental factors co-
operate in the pathogenesis of cardiovascular disease 
[2]. 
Angiotensin-Converting Enzyme (ACE) has an 
important impact on the structure and function of 
cardiovascular biology. ACE has a key role in the 
production of angiotensin-II and catabolism of 
bradykinin. Two peptides of ACE involved in the 
modulation of vascular tone and proliferation of smooth 
muscle cells [3]. Several studies have suggested that the 
genes encoding components of the Renin-Angiotensin 
System (RAS) is the candidate genes for cardiovascular 
disease, and recent reports suggest that genetic 
polymorphisms of the RAS have been associated with 
cardiovascular diseases [4, 5]. 
The human gene for ACE is located on 
chromosome 17 and contains a length polymorphism 
consisting the presence (insertion, I) or absence 
(deletion, D) of a 287 base pair DNA of intron 16, 
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which results in three genotypes: homozygotes DD and 
II and heterozygotes, ID [6]. ACE is a zinc 
metallopeptidase that converts angiotensin I to the 
potent vasoconstrictor angiotensin II which degrades 
bradykinin, a powerful vasodilator, both angiotensin I 
and II are for the regulation of vascular tone and cardiac 
functions [7]. The polymorphism is shown to be 
associated with the interpersonal variability of ACE 
levels in circulating blood [8]. The deletion allele at the 
gene site of ACE is associated with increased activity 
of plasma ACE [9]. Conflicting results have been 
reported regarding the association of ACE 
polymorphism with coronary artery disease [10, 11]. 
The purpose of this study was to investigate the 
correlation of the ACE/ID polymorphism with CAD in 
the evaluated population. 
 
2. Materials and Methods 
 
2.1  Materials 
The present study included 56 patients with CAD 
(42 males and 14 females, ages 35 to 55 years old) and 
56 apparently healthy individuals (41 males and 15 
females, ages 35 to 56 years old) as a control group. We 
collected information about the presence of categoric 
cardiac risk factors in every patient. Risk factors data 
were derived from patient interviews, contacting the 
referring physicians, and existing medical records. 
Systemic arterial hypertension was defined from 
documented history of high blood pressure or treatment 
with medication, diet, and/or exercise. A history of 
current smoking or cessation of smoking within 3 
months before testing was defined as the status of 
positive smoking. Hypercholesterolemia was 
determined on the basis of the answers to the following 
questions: “Has your physician ever told you that you 
need medications for high cholesterol?” “Are you 
currently taking cholesterol medications?” Answers to 
these questions often identified patients who were 
currently receiving cholesterol-lowering medications. 
Individuals were classified as having diabetes mellitus 
if they were previously diagnosed and determined by 
blood glucose levels and were in treatment with insulin 
or oral hypoglycemic agents. 
 
2.2  Collection of blood samples 
The 5ml of venous peripheral blood samples were 
collected in 15 ml polypropylene centrifugation tubes 
with screw cap that contained 20% EDTA with 3ml of 
nuclei lysis buffer (10 mM Tris-HCl, 400 mM NaCl 
and 2mM Na2EDTA, pH 8.2). The cell lysates were 
digested overnight at 37°C with 0.2ml of 10% SDS and 
0.5ml of a protease K solution (1mg protease K in 1% 
SDS and 2mM Na2EDTA). After digestion, 1 ml of 
saturated NaCl (approximately 6M) was added to each 
tube and shaken vigorously for 15 seconds, followed by 
centrifugation at 2500 rpm for 15 minutes. The 
supernatant containing the DNA was transferred to 
another 15ml polypropylene tube. Exactly 2 volumes 
absolute ethanol was added and mixed until the DNA 
was precipitated. The precipitated DNA was removed 
and transferred to Microcentrifuge tube containing 100-
200μl TE buffer (10mM Tris-HCl, 0.2mM Na2EDTA, 
pH 7.5). The DNA was allowed to dissolve for 2 hours 
at 37°C for quantification. 
 
2.3  Determination of ACE genotype 
According to the procedures of Miller et al., (1998) 
[12], the ACE genotypes of genomic DNA isolated 
from whole blood samples were determined by 
polymerase chain reaction. PCR amplification was 
carried for 35 cycles in a thermal cycler the mixture 
was denatured at 95°C for 5 minutes, then denaturing at 
95°C for 45 minutes, annealing at 65°C for 45 seconds 
and extension at 72°C for 2 minutes, the final extension 
cycle running for 10 minutes under the standard set of 
reaction conditions. The flanking primer pair 
5’CTGGAGACCACTCCCATCCTTTCT3' and 
5’GATGTGGCCATCACATTCGTCACGAT3’ for the 
DNA amplification was used and subsequently to 
increase the specificity of DD genotyping, PCR 
amplifications were also performed with I-specific 
primer pair 
5’TGGGACCACAGCGCCCGCCACTAC3' and 
5’TCGCCAG CCCTCCCATGCCCATAA3' in all the 
samples that were found to be DD after amplification 
with the flanking primers. The amplicon of the specific 
fragments was identified on 2% agarose gel containing 
ethidium bromide. 
 
2.4 Statistical analysis 
The statistical significance of all data was analyzed 
using the SPSS Version 12.0. Data were double 
entered, and the resulting sets of data were compared 
and checked for completeness and accuracy of the 
entry. The significant differences between the mean of 
the two groups was assessed with Student’s t-test, and 
the proportions were tested with the chi-square statistic. 
Differences in Vessel diseases were tested using 
ANOVA. A p-value <0.05 was considered to be 
statistically significant. Descriptive statistics were 
applied for calculating the distribution of various 
characteristics estimates. 
 
3. Results and Discussion 
 
The Angiotensin-I converting enzyme a key 
component of the renin-angiotensin system was 
responsible for the development of cardiovascular 
disease. An ACE inhibitor is known to significantly 
reduce mortality or the incidence of myocardial 
infarction in patients who have hypertension or 
ischemic heart disease [13-15]. In our study, we 
selected the individuals free from coronary risk factors 
as a control group. The age and gender distributions of 
patients with CAD in the study group and controls were 
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not similar. The Demographic and clinical 
characteristics of the patients and control subjects are 
presented in Table 1. The result of the table 1 is 
comparable with the previous study group of earlier 
reports which suggest that the prevalence of the ACE 
genotype specifically the insertion/deletion 
polymorphism in association with dilated 
cardiomyopathy, coronary-artery restenosis, 
hypertrophic cardiomyopathy, parental history of 
myocardial infarction [16] and cardiac hypertrophy 
with variable results was reported in a number of small 
case-control studies [17]. 
Total cholesterol, triglycerides and HDL-C levels 
showed significant differences between the study 
groups with CAD and were higher than the control 
group. LDL-C level was not significant in patients 
when compared to control (Table 2). 
 
Table 1. Demographic and clinical characteristics of the patients and controls 
 
Variables Coronary artery Disease (n = 112) Healthy control Subjects (n = 52) 
Age (years) 57.87 ± 8.91 50.23 ± 4.97 
Gender (n)   
Men 42 (80.4) 18 (72.0) 
Women 14 (19.6) 7 (28.0) 
Smoking habit (n)   
Smokers 22 (40) 6 (24) 
Ex- smokers 14 (25.5) 6 (24) 
No smokers 19 (34.5) 13 (52) 
Hypertension (n) 26 (47.3) 0 
Diabetes (n) 16 (29.1) 0 
Dislipidemia (n) 14 (25) 0 
Drug therapy   
Nitrates 44 (78.5) 0 
Aspirin 45 (80.3) 0 
ACE inhibitors 26 (46.4) 0 
Calcium- channel blockers 33 (58.9) 0 
Values in patients and controls are percentages 
 
Table 2. Serum lipid profile in both control and coronary artery disease patient groups. 
 
 CAD group (N = 56) Control group (N = 56) t- Value P- Value 
T. Cholesterol (mg/dl) 172.3 ± 39.42 148 ± 15.85 4.28 P < 0.001 
Triglyceride (mg/dl) 155.7 ± 76.53 110.71 ± 11.25 4.35 P < 0.001 
LDL-C (mg/dl) 114.28 ± 54.15 112 ± 13.07 -0.30 ns 
HDL-C (mg/dl) 45.39 ± 14.97 49.85 ± 3.85 -2.16 P < 0.05 
 
Values are expressed as mean ± SD, n = 56 (control) n = 56 (coronary artery diseases) P values difference between the control and the coronary 
artery disease statistical significant difference in two groups of (TC, TG and HDL-C) P < 0.001. Comparison of LDL-C statistical difference 
between from control and patients' values are not significant. > 0.05. CAD: coronary artery disease, HDL-C: high-density lipoprotein cholesterol, 
LDL-C: low-density lipoprotein cholesterol, ns: nonsignificant TC: total cholesterol. 
 
The present result agrees with the previous study 
which instigates that the lack of association between 
ACE gene polymorphism and serum cholesterol levels 
(HDL-C, LDL-C and triglycerides) in a group of 
patients with hypertension was observed [18]. On the 
other hand, Kawamoto (2002) has found a significant 
association between DD genotype and total cholesterol 
in a group of patients with hypertension and carotid 
atherosclerosis [19], while Chowdhury (1998) has 
found no association between DD genotype and total 
cholesterol in a group of Bangladesh patients with 
hypertension [20]. 
Comparison of the distribution of ACE gene 
genotypes among single, double and triple vessel CAD 
group and control group have shown no significant 
difference in gene polymorphism [2, 21]. However, 
these reports have been challenged by a series of 
negative studies [22, 23]. Our result on descriptive 
statistics of the population study with coronary 
angiography is presented in Table 3a. 
Table 3a. Distribution of ACE gene genotypes in CAD and the 
control group (overall). 
 
Genotype CAD n (%) Control n (%) t - value P value 
DD 14 (25) 12 (21.4) 0.45 ns 
ID 26 (46.6) 19 (35.7) 0.19 ns 
II 16 (28.6) 25 (42.9) 0.605 ns 
 
Values are expressed as mean ± SD, n = 14 (DD) n = 26 (ID) n = 16 (II) 
P values difference between the three groups control and the 
coronary artery disease statistical difference is not significant P >0.05 
P test values (0.45, 0.19 and 0.60). n = no of samples; CAD: coronary 
artery disease; DD: deletion; ID: insertion deletion II: insertion. 
 
Angiotensin-converting enzyme is responsible for 
the conversion of angiotensin I to the angiotensin II. 
Angiotensin II has been implicated in the pathogenesis 
of atherosclerosis CAD through the induction of 
hyperplasia and hypertrophy of smooth muscle cells, 
which increased the expression of platelet-derived 
growth factor and proto-oncogenes [24, 25]. In the 
present study, we have evaluated the association of the 
Gene polymorphism in patients with coronary artery disease                                                Ramakrishnan et al 
 
J. Adv. Lab. Res. Biol.                                                                                                                                                                                                                                             38 
ACE gene with CAD, and found that between CAD 
(single, double and triple vessel disease) and control 
groups (Table 3b, c, d) there was no significant 
difference in D and I allele frequency because of no 
association with the DD, ID, or II genotypes. The 
genotype analysis was observed that the DD genotype 
was slightly higher in CAD patients than controls (25% 
v. 21.4%). The ID genotype is 46.4% in patients while 
it is 44.6% in controls. The present data show contrary 
results to the previous reports of two studies performed 
in Turkish population which instigates that there was a 
significant association between DD polymorphism of 
ACE gene and CAD [26, 27]. In our study, there was no 
significant increase in the frequency of the DD 
genotype in CAD patients which were shown in Gel 
bands (Fig. 1 & 2a, b, c). The II genotype was little 
higher in controls (33.9%) than the patients (28.6%). 
However, the differences were not significant in 
genotype/phenotype interactions. 
 
Table 3b. Comparison of the distribution of ACE gene genotypes in 
single vessel CAD and the control group. 
 
Genotype CAD n (%) Control n (%) t - value P value 
DD 4 (26.7) 12 (21.4) 0.4364 ns 
ID 7 (46.6) 19 (35.7) 0.7724 ns 
II 4 (26.7) 25 (42.9) 1.14 ns 
 
Values are expressed as mean ± SD, n = 14 (DD) n = 26 (ID) n = 16 (II) 
P values difference between the three groups control and the 
coronary artery disease statistical difference is not significant P >0.05 
P test values (0.45, 0.19 and 0.60). n = no of samples; CAD: coronary 
artery disease; DD: deletion; ID: insertion deletion II: insertion. 
 
Table 3c. Comparison of the distribution of ACE gene genotypes in 
double vessel CAD and the control group. 
 
Genotype CAD n (%) Control n (%) t - value P value 
DD 6 (22.2) 12 (21.4) 0.0829 ns 
ID 13 (48.1) 19 (35.7) 1.0815 ns 
II 8 (29.6) 25 (42.9) 1.1662 ns 
 
Values are expressed as mean ± SD, n = 6 (DD) n = 13 (ID) n = 8 (II) P 
values difference between the three groups control and the 
coronary artery disease statistical difference is not significant P > 
0.05 P test values (0.08, 1.08 and 1.16). n = no of samples; CAD: 
coronary artery disease; DD: deletion; ID: insertion deletion II: 
insertion. 
 
Table 3d. Comparison of the distribution of ACE gene genotypes in 
triple vessel CAD and the control group. 
 
Genotype CAD n (%) Control n (%) t - value P value 
DD 4 (28.6) 12 (21.4) 0.5740 ns 
ID 6 (42.8) 19 (35.7) 0.4918 ns 
II 4 (28.6) 25 (42.9) 0.9767 ns 
 
Values are expressed as mean ± SD, n = 4 (DD) n = 6 (ID) n = 4 (II) P 
values difference between the three groups control and the 
coronary artery disease statistical difference is not significant P > 
0.05 P test values (0.57, 0.49 and 0.97). n = no of samples; CAD: 
coronary artery disease; DD: deletion; ID: insertion deletion II: 
insertion. 
 
 
 
Fig. 1. Analysis of Polymerase chain reaction for angiotensin-
converting enzyme gene polymorphism in CAD and control. The 
gel is showing the I and D alleles in control. 
 
 
 
Fig. 2a. Gel shows the I and D alleles in CAD patients. 
 
 
 
Fig. 2b. Gel shows the I and D alleles in CAD patients. 
 
 
 
Fig. 2c. Gel shows the I specific alleles in CAD patients. 
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Although the precursors of ACE gene 
polymorphism on the prediction of clinical 
manifestation of CAD may be genetically determined, 
the CAD event rates and their occurrences with 
differences in the population appear to be largely 
determined by environment and lifestyle [28]. Some 
studies have suggested that ACE polymorphism may be 
relevant to the factors that predispose individuals to the 
development of atherosclerosis than being the direct 
cause of CAD itself. The mechanism by which the ACE 
I/D genotype may predispose an individual to the 
development of CAD remains unclear. Further efforts 
should be made to elucidate the specific nature of 
epidemiology. 
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